A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer\'s disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.
Epistemonikos ID: b49226d35097fb8ea5cfb4b9a21d8af65fc580cb
First added on: May 07, 2024